(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.
The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.
- Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Elicio Therapeutics, General Oncology, Inc., ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology, Eucure Biopharma, Panbela Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals, Novartis Pharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment
- Emerging Pancreatic Ductal Adenocarcinoma therapies such as – ELI-002, Melphalan, ZB131, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.
- In January 2022, Jiangsu Alphamab Biopharmaceuticals initiated a multicenter, randomized, double-blind Phase III study to assess the efficacy and safety of KN046 combined with Gemcitabine and NabPaclitaxel versus placebo combined with Gemcitabine and Nab-Paclitaxel in first line Advanced Pancreatic Ductal Adenocarcinoma subjects (ENREACH-PDAC-01)
- In July 2022, Cend Therapeutics, Inc. announced that The Lancet Gastroenterology and Hepatology published data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”)
- In July 2022, I-Mab announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma
- In June 2022, BioNTech SE announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). Feasibility of the process of profiling each patient’s tumor to inform individualized vaccine design and on-demand manufacturing of iNeST in a clinically relevant timeframe was confirmed. The preliminary results showed a favorable safety profile as well as encouraging signs of clinical activity
- In June 2022, BioLineRx Ltd. announced that the Company had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical company based in China, to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.
- In May 2022, Elicio Therapeutics, announced that it had entered into a clinical supply agreement with Regeneron to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. The combination therapy will be studied in KRAS-driven tumors, including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC), and unresectable, locally advanced, or oligometastatic pancreatic ductal adenocarcinoma (PDAC)
- In November 2021, Alphamab Oncology announced that the IND application for phase III registration study(KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) was approved by the Center for Drug Evaluation (CDE) of the NMPA
Pancreatic Ductal Adenocarcinoma Overview
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It is the most prevalent type of pancreatic neoplasm, and it is developed in the exocrine compartment and accounts for more than 90% of pancreatic cancer cases.
Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment
Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:
- ELI-002: Elicio Therapeutics
- Melphalan: General Oncology, Inc.
- RMC-6236: Revolution Medicines
- AMP 945: Amplia Therapeutics
- ZB131: ZielBio
- CEND-1: Lisata Therapeutics, Inc.
- Onvansertib: Cardiff Oncology
- YH003: Eucure Biopharma
- SBP-101: Panbela Therapeutics, Inc.
- KN046: Jiangsu Alphamab Biopharmaceuticals
- NIS793: Novartis Pharmaceuticals
Route of Administration
Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment
- Pancreatic Ductal Adenocarcinoma Assessment by Product Type
- Pancreatic Ductal Adenocarcinoma By Stage and Product Type
- Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
- Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
- Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type
DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies
Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:
Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
Pancreatic Ductal Adenocarcinoma Pipeline Analysis:
The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
- Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies
Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers
- Increasing pervasiveness of the disease, increasing demand of targeted therapy, are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.
Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers
- However, Lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.
Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight
- Coverage: Global
- Key Pancreatic Ductal Adenocarcinoma Companies: Elicio Therapeutics, General Oncology, Inc., ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology, Eucure Biopharma, Panbela Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals, Novartis Pharmaceuticals, and others
- Key Pancreatic Ductal Adenocarcinoma Therapies: ELI-002, Melphalan, ZB131, CEND-1, Onvansertib, YH003, SBP-101, KN046, NIS793, and others
- Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
- Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers
Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials
Table of Contents
| 1 | Pancreatic Ductal Adenocarcinoma Report Introduction |
| 2 | Pancreatic Ductal Adenocarcinoma Executive Summary |
| 3 | Pancreatic Ductal Adenocarcinoma Overview |
| 4 | Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment |
| 5 | Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics |
| 6 | Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III) |
| 7 | Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II) |
| 8 | Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I) |
| 9 | Pancreatic Ductal Adenocarcinoma Preclinical Stage Products |
| 10 | Pancreatic Ductal Adenocarcinoma Therapeutics Assessment |
| 11 | Pancreatic Ductal Adenocarcinoma Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Pancreatic Ductal Adenocarcinoma Key Companies |
| 14 | Pancreatic Ductal Adenocarcinoma Key Products |
| 15 | Pancreatic Ductal Adenocarcinoma Unmet Needs |
| 16 | Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers |
| 17 | Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion |
| 18 | Pancreatic Ductal Adenocarcinoma Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Latest Reports:
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Trending Reports:
- Interbody Cages Market
- Hip Replacement Devices Market
- Ada-Scid Competitive Landscape
- Adrenal Cortex Neoplasms Market
- Bone Anchored Hearing Systems Market
- Meningioma Market
To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog’s By DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187